var data={"title":"Erysipelothrix infection","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Erysipelothrix infection</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/erysipelothrix-infection/contributors\" class=\"contributor contributor_credentials\">Annette C Reboli, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/erysipelothrix-infection/contributors\" class=\"contributor contributor_credentials\">Daniel J Sexton, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/erysipelothrix-infection/contributors\" class=\"contributor contributor_credentials\">Elinor L Baron, MD, DTMH</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/erysipelothrix-infection/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Aug 31, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><em>Erysipelothrix rhusiopathiae</em> is a pleomorphic, non&ndash;spore forming, gram-positive bacillus capable of causing self-limited soft tissue infection or serious systemic infection. <em>E. rhusiopathiae </em>is widespread in nature around the world and also infects domestic and marine animals; it is found in sheep, horses, cattle, chickens, turkeys, crabs, fish, dogs, and cats [<a href=\"https://www.uptodate.com/contents/erysipelothrix-infection/abstract/1\" class=\"abstract_t\">1</a>]. The risk may be highest from swine exposure because of the large number of exposed farmers.</p><p>Infection in humans is usually due to occupational exposure. Thus, slaughterhouse workers, butchers, fishermen, aquarium workers, farmers, and veterinarians are at risk for infection with <em>E. rhusiopathiae</em> [<a href=\"https://www.uptodate.com/contents/erysipelothrix-infection/abstract/2-5\" class=\"abstract_t\">2-5</a>].</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">PATHOGENESIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Little is known about the pathogenesis of human <em>E. rhusiopathiae</em> infection. The following observations have been made in vitro and in animal studies:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><em>E. rhusiopathiae</em> is a virulent organism with a capsule that resists phagocytosis and may contribute to intracellular survival (in the absence of opsonization with specific antibody) [<a href=\"https://www.uptodate.com/contents/erysipelothrix-infection/abstract/6,7\" class=\"abstract_t\">6,7</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Intracellular survival of virulent organisms in macrophages is associated with reduced stimulation of the oxidative respiratory burst [<a href=\"https://www.uptodate.com/contents/erysipelothrix-infection/abstract/7\" class=\"abstract_t\">7</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The SpaA protein is a surface antigen of <em>E. rhusiopathiae</em>. The pathogenic significance of this protein was suggested in a mouse model in which exposure to SpaA antigen was protective in a vaccination system [<a href=\"https://www.uptodate.com/contents/erysipelothrix-infection/abstract/8\" class=\"abstract_t\">8</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The enzymes neuraminidase and hyaluronidase may contribute to the pathogenicity of <em>Erysipelothrix</em> [<a href=\"https://www.uptodate.com/contents/erysipelothrix-infection/abstract/9\" class=\"abstract_t\">9</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Other virulence factors include cell wall&ndash;associated proteins such as transporter and adhesion proteins [<a href=\"https://www.uptodate.com/contents/erysipelothrix-infection/abstract/10\" class=\"abstract_t\">10</a>].</p><p/><p class=\"headingAnchor\" id=\"H3\"><span class=\"h1\">CLINICAL MANIFESTATIONS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The clinical spectrum of human infection includes three major forms of disease:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Localized cutaneous (erysipeloid) infection</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Diffuse cutaneous infection</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Systemic infection (bacteremia with or without endocarditis)</p><p/><p class=\"headingAnchor\" id=\"H4\"><span class=\"h2\">Localized cutaneous infection</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The most common form of human infection due to <em>E. rhusiopathiae</em> is the localized cutaneous form, known as erysipeloid of Rosenbach [<a href=\"https://www.uptodate.com/contents/erysipelothrix-infection/abstract/11\" class=\"abstract_t\">11</a>]. When localized infection occurs, it is a usually subacute cellulitis and involves the fingers <span class=\"nowrap\">and/or</span> hands (the sites of exposure). Abrasions or wounds of the skin serve as the portal of entry of the organism. As an example, erysipeloid has been described on the fingers or hands of fisherman or seafood packers who suffer minor trauma while handling contaminated shrimp, crab, or fish [<a href=\"https://www.uptodate.com/contents/erysipelothrix-infection/abstract/12,13\" class=\"abstract_t\">12,13</a>]. Infection can also occur following cat or dog bites. In a review from 18 emergency departments in the United States, <em>E. rhusiopathiae</em> was isolated from 2 of 57 patients with infected cat bites [<a href=\"https://www.uptodate.com/contents/erysipelothrix-infection/abstract/14\" class=\"abstract_t\">14</a>].</p><p>The incubation period following inoculation may last two to seven days. Symptoms begin with pain at the site of inoculation (described as throbbing, itching, burning, or tingling). The skin lesion typically progresses slowly from a small red macule at the inoculation site to a well-developed violaceous lesion with central clearing and a raised border. Swelling is typically minimal; patients typically complain of stiffness and pain in the involved fingers. Local lymphangitis and adenitis occur in approximately 30 percent of cases. Systemic symptoms such as high fever or chills are uncommon (about 10 percent of patients) [<a href=\"https://www.uptodate.com/contents/erysipelothrix-infection/abstract/15\" class=\"abstract_t\">15</a>].</p><p class=\"headingAnchor\" id=\"H5\"><span class=\"h2\">Diffuse cutaneous infection</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Diffuse cutaneous disease is characterized by proximal progression of involvement from the inoculation site <span class=\"nowrap\">and/or</span> involvement of additional sites; such cases are rare [<a href=\"https://www.uptodate.com/contents/erysipelothrix-infection/abstract/11\" class=\"abstract_t\">11</a>]. Lesions may be urticarial or bullous, and these patients frequently have fever and arthralgia. Blood cultures are usually negative [<a href=\"https://www.uptodate.com/contents/erysipelothrix-infection/abstract/11\" class=\"abstract_t\">11</a>].</p><p>Most patients with diffuse cutaneous infection have the same types of exposures as those with localized cutaneous infection. However, eating contaminated seafood or undercooked pork has been associated with diffuse cutaneous disease. In such cases, it is presumed that bacteremia precedes the appearance of diffuse cutaneous disease.</p><p class=\"headingAnchor\" id=\"H6\"><span class=\"h2\">Systemic infection</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Systemic infection with bacteremia (with or without endocarditis) is relatively uncommon. Most patients present with fever. Approximately 40 percent of patients with systemic infection have antecedent or concurrent skin lesions suggestive of erysipeloid [<a href=\"https://www.uptodate.com/contents/erysipelothrix-infection/abstract/3\" class=\"abstract_t\">3</a>]. Cutaneous serpiginous lesions or multiple bullous lesions on the trunk and extremities may be seen. Patients with severe underlying liver or heart disease and systemic infection due to <em>Erysipelothrix</em> infection may have a clinical presentation resembling gram-negative sepsis [<a href=\"https://www.uptodate.com/contents/erysipelothrix-infection/abstract/16\" class=\"abstract_t\">16</a>].</p><p>The epidemiologic exposures in patients with systemic infection are the same as those for localized cutaneous infection; persistent bacteremia has been reported after the ingestion of contaminated meat. Chronic liver disease is an important predisposing factor; more than one-third of patients with systemic infection are alcoholics [<a href=\"https://www.uptodate.com/contents/erysipelothrix-infection/abstract/3,11,17\" class=\"abstract_t\">3,11,17</a>]. Bacteremia may also be seen in other immunocompromised patients, especially those receiving corticosteroid <span class=\"nowrap\">and/or</span> cytotoxic drug therapy [<a href=\"https://www.uptodate.com/contents/erysipelothrix-infection/abstract/16,18,19\" class=\"abstract_t\">16,18,19</a>].</p><p class=\"headingAnchor\" id=\"H7\"><span class=\"h3\">Endocarditis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><em>E. rhusiopathiae</em> bacteremia is often complicated by endocarditis; in one report, 90 percent of 49 cases of serious infection had proven or presumed endocarditis [<a href=\"https://www.uptodate.com/contents/erysipelothrix-infection/abstract/3\" class=\"abstract_t\">3</a>]. However, this figure may be a falsely elevated rate due to reporting bias in case reports, since a number of cases with bacteremia in the absence of endocarditis have also been reported [<a href=\"https://www.uptodate.com/contents/erysipelothrix-infection/abstract/16,18-21\" class=\"abstract_t\">16,18-21</a>].</p><p>Nearly all reported cases of endocarditis have involved native heart valves, with propensity for involvement of the aortic valve [<a href=\"https://www.uptodate.com/contents/erysipelothrix-infection/abstract/3,22\" class=\"abstract_t\">3,22</a>]. <em>Erysipelothrix</em> endocarditis frequently causes extensive valve destruction. In one series, one-third of patients died and an additional one-third required valve replacement [<a href=\"https://www.uptodate.com/contents/erysipelothrix-infection/abstract/3\" class=\"abstract_t\">3</a>].</p><p>Complications of <em>Erysipelothrix</em> endocarditis may include congestive heart failure, valve perforation, myocardial abscess, cerebral infarctions, and acute renal failure due to proliferative glomerulonephritis [<a href=\"https://www.uptodate.com/contents/erysipelothrix-infection/abstract/23\" class=\"abstract_t\">23</a>].</p><p class=\"headingAnchor\" id=\"H8\"><span class=\"h2\">Other manifestations</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Uncommon forms of infection due to <em>E. rhusiopathiae</em> include brain abscess, meningitis, endophthalmitis, intra-abdominal abscess, psoas abscess, osteomyelitis (including vertebral osteomyelitis), septic arthritis (including infection of prosthetic joints), epidural and paravertebral abscesses, pneumonia, necrotizing fasciitis, and peritoneal dialysis-related peritonitis with bacteremia [<a href=\"https://www.uptodate.com/contents/erysipelothrix-infection/abstract/18,24-34\" class=\"abstract_t\">18,24-34</a>].</p><p class=\"headingAnchor\" id=\"H9\"><span class=\"h1\">DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>A provisional diagnosis can often be made based on a history of appropriate epidemiologic exposure together with the characteristic physical findings. <em>Erysipelothrix </em>infection might be suspected in cutaneous or systemic gram-positive infections that fail to respond to <a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">vancomycin</a>. Gram stain and culture of aspirated material are often negative because the organism is deep within the dermis.</p><p>Organisms may be isolated from the blood with routine commercial blood culture media; growth is usually recognized in two to three days. However, errors in identification can occur; the organism has been misidentified as <em>Lactobacillus</em> or <em>Enterococcus</em> species [<a href=\"https://www.uptodate.com/contents/erysipelothrix-infection/abstract/35\" class=\"abstract_t\">35</a>]. Matrix-assisted laser <span class=\"nowrap\">desorption/ionization&ndash;time</span> of flight mass spectroscopy (MALDI-TOF MS) accurately and rapidly identifies <em>Erysipelothrix</em> [<a href=\"https://www.uptodate.com/contents/erysipelothrix-infection/abstract/36\" class=\"abstract_t\">36</a>].</p><p class=\"headingAnchor\" id=\"H1057147395\"><span class=\"h1\">DIFFERENTIAL DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The differential diagnosis of localized cutaneous infection (erysipeloid) includes streptococcal or staphylococcal cellulitis. The diagnosis of erysipeloid is favored by a history of occupational exposure, lesions on the fingers, a subacute course, violaceous hue (as opposed to erythema), absence of suppuration, absence of pitting edema, and pain out of proportion with physical findings.</p><p class=\"headingAnchor\" id=\"H10\"><span class=\"h1\">TREATMENT</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Erysipeloid skin lesions may resolve in the absence of specific therapy; spontaneous resolution typically occurs within three weeks [<a href=\"https://www.uptodate.com/contents/erysipelothrix-infection/abstract/37\" class=\"abstract_t\">37</a>]. However, appropriate antibiotic therapy shortens the clinical illness and reduces the risk of relapse [<a href=\"https://www.uptodate.com/contents/erysipelothrix-infection/abstract/22\" class=\"abstract_t\">22</a>]. Local heat may be helpful for patients with arthritis and painful, swollen lesions. Surgical incision or debridement of localized lesions is not indicated.</p><p class=\"headingAnchor\" id=\"H11\"><span class=\"h2\">Antibiotic susceptibility</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Penicillin is the drug of choice for all forms of <em>Erysipelothrix</em> infection based on in vitro data; there are no comparative clinical trials (<a href=\"image.htm?imageKey=ID%2F73058\" class=\"graphic graphic_table graphicRef73058 \">table 1</a>) [<a href=\"https://www.uptodate.com/contents/erysipelothrix-infection/abstract/2-5,16,17,19,20,22,37-39\" class=\"abstract_t\">2-5,16,17,19,20,22,37-39</a>]. In vitro, penicillin and <a href=\"topic.htm?path=imipenem-and-cilastatin-drug-information\" class=\"drug drug_general\">imipenem</a> are the most active agents; other active agents include other beta-lactam antibiotics such as cephalosporins, fluoroquinolones, <a href=\"topic.htm?path=clindamycin-drug-information\" class=\"drug drug_general\">clindamycin</a>, <a href=\"topic.htm?path=daptomycin-drug-information\" class=\"drug drug_general\">daptomycin</a>, and <a href=\"topic.htm?path=linezolid-drug-information\" class=\"drug drug_general\">linezolid</a> [<a href=\"https://www.uptodate.com/contents/erysipelothrix-infection/abstract/40,41\" class=\"abstract_t\">40,41</a>]. Agents that are not consistently active against <em>Erysipelothrix</em> include macrolides, tetracyclines, and <a href=\"topic.htm?path=chloramphenicol-drug-information\" class=\"drug drug_general\">chloramphenicol</a>; these should not be used in the treatment of disseminated infection.</p><p><em>E. rhusiopathiae</em> is typically resistant to sulfonamides, <a href=\"topic.htm?path=trimethoprim-sulfamethoxazole-co-trimoxazole-drug-information\" class=\"drug drug_general\">trimethoprim-sulfamethoxazole</a>, <a href=\"topic.htm?path=vancomycin-drug-information\" class=\"drug drug_general\">vancomycin</a>, and aminoglycosides [<a href=\"https://www.uptodate.com/contents/erysipelothrix-infection/abstract/3,38,39\" class=\"abstract_t\">3,38,39</a>]. Resistance to vancomycin is a clinically relevant characteristic, since this antibiotic is often used empirically in treatment of gram-positive infections. However, limited data suggest that <em>Erysipelothrix</em> is susceptible to <a href=\"topic.htm?path=daptomycin-drug-information\" class=\"drug drug_general\">daptomycin</a> [<a href=\"https://www.uptodate.com/contents/erysipelothrix-infection/abstract/40\" class=\"abstract_t\">40</a>].</p><p class=\"headingAnchor\" id=\"H12\"><span class=\"h2\">Clinical approach</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The approach to antibiotic therapy depends on the clinical manifestations and results of blood cultures (<a href=\"image.htm?imageKey=ID%2F73058\" class=\"graphic graphic_table graphicRef73058 \">table 1</a>).</p><p>For localized cutaneous infection, oral therapy with <a href=\"topic.htm?path=penicillin-v-potassium-oral-drug-information\" class=\"drug drug_general\">penicillin V</a> (500 mg every 6 hours) should be administered; <a href=\"topic.htm?path=cephalexin-drug-information\" class=\"drug drug_general\">cephalexin</a> (500 mg every 6 hours) is an acceptable regimen in the absence of immediate hypersensitivity to penicillin. In the setting of penicillin allergy, <a href=\"topic.htm?path=ciprofloxacin-drug-information\" class=\"drug drug_general\">ciprofloxacin</a> (250 mg every 12 hours) or <a href=\"topic.htm?path=clindamycin-drug-information\" class=\"drug drug_general\">clindamycin</a> (300 mg every 8 hours) may be administered. Seven days of therapy is usually curative.</p><p>Parenteral therapy should be administered with <a href=\"topic.htm?path=penicillin-g-intravenous-and-short-acting-intramuscular-drug-information\" class=\"drug drug_general\">penicillin G</a> (2 to 4 million units every 4 hours) for patients with diffuse cutaneous disease or systemic infection. Alternative therapies include <a href=\"topic.htm?path=ceftriaxone-drug-information\" class=\"drug drug_general\">ceftriaxone</a> (2 g once daily), <a href=\"topic.htm?path=imipenem-and-cilastatin-drug-information\" class=\"drug drug_general\">imipenem</a> (500 mg every 6 hours), or a fluoroquinolone (<a href=\"topic.htm?path=ciprofloxacin-drug-information\" class=\"drug drug_general\">ciprofloxacin</a> 400 mg every 12 hours or <a href=\"topic.htm?path=levofloxacin-drug-information\" class=\"drug drug_general\">levofloxacin</a> 500 mg once daily) or <a href=\"topic.htm?path=daptomycin-drug-information\" class=\"drug drug_general\">daptomycin</a> (6 <span class=\"nowrap\">mg/kg</span> intravenously once daily) [<a href=\"https://www.uptodate.com/contents/erysipelothrix-infection/abstract/40\" class=\"abstract_t\">40</a>].</p><p>The optimal duration of therapy has not been evaluated in clinical trials. Treatment duration should be based on the clinical response, the underlying health of the patient, and whether endocarditis is known to be present or absent. Many patients with diffuse cutaneous disease can be switched to oral therapy after clinical response occurs. Short courses of therapy (eg, one week) are often curative in such patients. Duration of therapy in bacteremic patients without endocarditis is a clinical judgment; some experts favor a minimum of four weeks of therapy even when endocarditis or signs of metastatic infection are not present [<a href=\"https://www.uptodate.com/contents/erysipelothrix-infection/abstract/3,22\" class=\"abstract_t\">3,22</a>]. Two weeks of intravenous therapy followed by two to four weeks of oral therapy has also been successful [<a href=\"https://www.uptodate.com/contents/erysipelothrix-infection/abstract/22\" class=\"abstract_t\">22</a>].</p><p class=\"headingAnchor\" id=\"H13\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><em>Erysipelothrix rhusiopathiae</em> is a gram-positive bacillus capable of causing self-limited soft tissue infection or serious systemic infection in humans. It is widespread in nature and infects domestic animals. Infection in humans is usually due to occupational exposure. Slaughterhouse workers, butchers, fishermen, farmers, and veterinarians are at risk for infection with <em>E. rhusiopathiae</em>. (See <a href=\"#H1\" class=\"local\">'Introduction'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>There are three major forms of disease: localized cutaneous (erysipeloid) infection, diffuse cutaneous infection, and systemic infection (bacteremia with or without endocarditis). (See <a href=\"#H3\" class=\"local\">'Clinical manifestations'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Localized cutaneous infection is a subacute cellulitis that usually involves the fingers <span class=\"nowrap\">and/or</span> hands; abrasions or wounds of the skin serve as the portal of entry of the organism. Following an incubation period of two to seven days, symptoms begin with pain at the site of inoculation. The skin lesion typically progresses from a small red macule at the inoculation site to a well-developed violaceous lesion with central clearing and a raised border. (See <a href=\"#H4\" class=\"local\">'Localized cutaneous infection'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Diffuse cutaneous disease is characterized by proximal progression of involvement from the inoculation site <span class=\"nowrap\">and/or</span> involvement of additional sites. Lesions may be urticarial or bullous, and these patients frequently have fever and arthralgia. (See <a href=\"#H5\" class=\"local\">'Diffuse cutaneous infection'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Systemic infection with bacteremia (with or without endocarditis) presents with fever; approximately 40 percent of patients with systemic infection also have antecedent or concurrent skin lesions suggestive of erysipeloid. <em>E. rhusiopathiae</em> bacteremia is often complicated by endocarditis. (See <a href=\"#H6\" class=\"local\">'Systemic infection'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A provisional diagnosis can be made based on a history of appropriate epidemiologic exposure together with the characteristic physical findings. Organisms may be isolated from the blood with routine commercial blood culture media; growth is usually recognized in two to three days. (See <a href=\"#H9\" class=\"local\">'Diagnosis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For treatment of localized cutaneous infection, we suggest oral therapy with <a href=\"topic.htm?path=penicillin-v-potassium-oral-drug-information\" class=\"drug drug_general\">penicillin V</a> (<a href=\"grade.htm?i=6\" class=\"grade\">Grade 2C</a>). In the setting of penicillin allergy, <a href=\"topic.htm?path=cephalexin-drug-information\" class=\"drug drug_general\">cephalexin</a> (in the absence of immediate hypersensitivity to penicillin), <a href=\"topic.htm?path=ciprofloxacin-drug-information\" class=\"drug drug_general\">ciprofloxacin</a> or <a href=\"topic.htm?path=clindamycin-drug-information\" class=\"drug drug_general\">clindamycin</a> are acceptable alternatives. Treatment duration is seven days; dosing is outlined in the Table (<a href=\"image.htm?imageKey=ID%2F73058\" class=\"graphic graphic_table graphicRef73058 \">table 1</a>). (See <a href=\"#H12\" class=\"local\">'Clinical approach'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For treatment of diffuse cutaneous disease, we suggest parenteral therapy with <a href=\"topic.htm?path=penicillin-g-intravenous-and-short-acting-intramuscular-drug-information\" class=\"drug drug_general\">penicillin G</a> (<a href=\"grade.htm?i=6\" class=\"grade\">Grade 2C</a>). Alternative therapies include <a href=\"topic.htm?path=ceftriaxone-drug-information\" class=\"drug drug_general\">ceftriaxone</a>, <a href=\"topic.htm?path=imipenem-and-cilastatin-drug-information\" class=\"drug drug_general\">imipenem</a>, a fluoroquinolone, or <a href=\"topic.htm?path=daptomycin-drug-information\" class=\"drug drug_general\">daptomycin</a> (<a href=\"image.htm?imageKey=ID%2F73058\" class=\"graphic graphic_table graphicRef73058 \">table 1</a>). (See <a href=\"#H12\" class=\"local\">'Clinical approach'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For treatment of systemic infection with bacteremia (with or without endocarditis), we suggest parenteral therapy with <a href=\"topic.htm?path=penicillin-g-intravenous-and-short-acting-intramuscular-drug-information\" class=\"drug drug_general\">penicillin G</a> (<a href=\"grade.htm?i=6\" class=\"grade\">Grade 2C</a>). Alternative therapies include <a href=\"topic.htm?path=ceftriaxone-drug-information\" class=\"drug drug_general\">ceftriaxone</a>, <a href=\"topic.htm?path=imipenem-and-cilastatin-drug-information\" class=\"drug drug_general\">imipenem</a>, a fluoroquinolone, or <a href=\"topic.htm?path=daptomycin-drug-information\" class=\"drug drug_general\">daptomycin</a>. Treatment duration is at least four weeks; dosing is outlined in the Table (<a href=\"image.htm?imageKey=ID%2F73058\" class=\"graphic graphic_table graphicRef73058 \">table 1</a>). (See <a href=\"#H12\" class=\"local\">'Clinical approach'</a> above.)</p><p/></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/erysipelothrix-infection/abstract/1\" class=\"nounderline abstract_t\">Wang Q, Fidalgo S, Chang BJ, et al. The detection and recovery of Erysipelothrix spp. in meat and abattoir samples in Western Australia. J Appl Microbiol 2002; 92:844.</a></li><li><a href=\"https://www.uptodate.com/contents/erysipelothrix-infection/abstract/2\" class=\"nounderline abstract_t\">Veraldi S, Girgenti V, Dassoni F, Gianotti R. Erysipeloid: a review. Clin Exp Dermatol 2009; 34:859.</a></li><li><a href=\"https://www.uptodate.com/contents/erysipelothrix-infection/abstract/3\" class=\"nounderline abstract_t\">Gorby GL, Peacock JE Jr. Erysipelothrix rhusiopathiae endocarditis: microbiologic, epidemiologic, and clinical features of an occupational disease. Rev Infect Dis 1988; 10:317.</a></li><li><a href=\"https://www.uptodate.com/contents/erysipelothrix-infection/abstract/4\" class=\"nounderline abstract_t\">Wang Q, Chang BJ, Riley TV. Erysipelothrix rhusiopathiae. Vet Microbiol 2010; 140:405.</a></li><li><a href=\"https://www.uptodate.com/contents/erysipelothrix-infection/abstract/5\" class=\"nounderline abstract_t\">McNamara DR, Zitterkopf NL, Baddour LM. A woman with a lesion on her finger and bacteremia. Clin Infect Dis 2005; 41:1005.</a></li><li><a href=\"https://www.uptodate.com/contents/erysipelothrix-infection/abstract/6\" class=\"nounderline abstract_t\">Shimoji Y, Yokomizo Y, Sekizaki T, et al. Presence of a capsule in Erysipelothrix rhusiopathiae and its relationship to virulence for mice. Infect Immun 1994; 62:2806.</a></li><li><a href=\"https://www.uptodate.com/contents/erysipelothrix-infection/abstract/7\" class=\"nounderline abstract_t\">Shimoji Y. Pathogenicity of Erysipelothrix rhusiopathiae: virulence factors and protective immunity. Microbes Infect 2000; 2:965.</a></li><li><a href=\"https://www.uptodate.com/contents/erysipelothrix-infection/abstract/8\" class=\"nounderline abstract_t\">Cheun HI, Kawamoto K, Hiramatsu M, et al. Protective immunity of SpaA-antigen producing Lactococcus lactis against Erysipelothrix rhusiopathiae infection. J Appl Microbiol 2004; 96:1347.</a></li><li><a href=\"https://www.uptodate.com/contents/erysipelothrix-infection/abstract/9\" class=\"nounderline abstract_t\">Abrashev I, Orozova P. Erysipelothrix rhusiopathiae neuraminidase and its role in pathogenicity. Z Naturforsch C 2006; 61:434.</a></li><li><a href=\"https://www.uptodate.com/contents/erysipelothrix-infection/abstract/10\" class=\"nounderline abstract_t\">Wang Y, Li J, Zhang A, et al. iTRAQ-based quantitative proteomic analysis reveals potential virulence factors of Erysipelothrix rhusiopathiae. J Proteomics 2017; 160:28.</a></li><li class=\"breakAll\">Hand WL, Ho H. Erysipelothrix. In: Current Therapy of Infectious Disease, 2nd ed, Schlossberg D (Ed), Mosby, Inc, St. Louis 2001. p.499.</li><li><a href=\"https://www.uptodate.com/contents/erysipelothrix-infection/abstract/12\" class=\"nounderline abstract_t\">Collier DN. Cutaneous infections from coastal and marine bacteria. Dermatol Ther 2002; 15:1.</a></li><li><a href=\"https://www.uptodate.com/contents/erysipelothrix-infection/abstract/13\" class=\"nounderline abstract_t\">Burke WA, Jones BE. Cutaneous infections of the coast. N C Med J 1987; 48:421.</a></li><li><a href=\"https://www.uptodate.com/contents/erysipelothrix-infection/abstract/14\" class=\"nounderline abstract_t\">Talan DA, Citron DM, Abrahamian FM, et al. Bacteriologic analysis of infected dog and cat bites. Emergency Medicine Animal Bite Infection Study Group. N Engl J Med 1999; 340:85.</a></li><li><a href=\"https://www.uptodate.com/contents/erysipelothrix-infection/abstract/15\" class=\"nounderline abstract_t\">NELSON E. Five hundred cases of erysipeloid. Rocky Mt Med J 1955; 52:40.</a></li><li><a href=\"https://www.uptodate.com/contents/erysipelothrix-infection/abstract/16\" class=\"nounderline abstract_t\">Ognibene FP, Cunnion RE, Gill V, et al. Erysipelothrix rhusiopathiae bacteremia presenting as septic shock. Am J Med 1985; 78:861.</a></li><li><a href=\"https://www.uptodate.com/contents/erysipelothrix-infection/abstract/17\" class=\"nounderline abstract_t\">Schuster MG, Brennan PJ, Edelstein P. Persistent bacteremia with Erysipelothrix rhusiopathiae in a hospitalized patient. Clin Infect Dis 1993; 17:783.</a></li><li><a href=\"https://www.uptodate.com/contents/erysipelothrix-infection/abstract/18\" class=\"nounderline abstract_t\">Upapan P, Chayakulkeeree M. Erysipelothrix rhusiopathiae bacteremia without endocarditis associated with psoas abscess: the first case report in Thailand. J Med Assoc Thai 2014; 97 Suppl 3:S232.</a></li><li><a href=\"https://www.uptodate.com/contents/erysipelothrix-infection/abstract/19\" class=\"nounderline abstract_t\">Drekonja DM. Erysipelothrix bacteremia without endocarditis: rare event or under-reported occurrence? Diagn Microbiol Infect Dis 2013; 77:280.</a></li><li><a href=\"https://www.uptodate.com/contents/erysipelothrix-infection/abstract/20\" class=\"nounderline abstract_t\">Jones N, Khoosal M. Erysipelothrix rhusiopathiae septicemia in a neonate. Clin Infect Dis 1997; 24:511.</a></li><li><a href=\"https://www.uptodate.com/contents/erysipelothrix-infection/abstract/21\" class=\"nounderline abstract_t\">Tan EM, Marcelin JR, Adeel N, et al. Erysipelothrix rhusiopathiae bloodstream infection - A 22-year experience at Mayo Clinic, Minnesota. Zoonoses Public Health 2017; 64:e65.</a></li><li><a href=\"https://www.uptodate.com/contents/erysipelothrix-infection/abstract/22\" class=\"nounderline abstract_t\">Reboli AC, Farrar WE. Erysipelothrix rhusiopathiae: an occupational pathogen. Clin Microbiol Rev 1989; 2:354.</a></li><li><a href=\"https://www.uptodate.com/contents/erysipelothrix-infection/abstract/23\" class=\"nounderline abstract_t\">Fern&aacute;ndez-Crespo P, Serra A, Bonet J, Gimenez M. Acute oliguric renal failure in a patient with an Erysipelothrix rhusiopathiae bacteremia and endocarditis. Nephron 1996; 74:231.</a></li><li><a href=\"https://www.uptodate.com/contents/erysipelothrix-infection/abstract/24\" class=\"nounderline abstract_t\">Ruiz ME, Richards JS, Kerr GS, Kan VL. Erysipelothrix rhusiopathiae septic arthritis. Arthritis Rheum 2003; 48:1156.</a></li><li><a href=\"https://www.uptodate.com/contents/erysipelothrix-infection/abstract/25\" class=\"nounderline abstract_t\">Simionescu R, Grover S, Shekar R, West BC. Necrotizing fasciitis caused by Erysipelothrix rhusiopathiae. South Med J 2003; 96:937.</a></li><li><a href=\"https://www.uptodate.com/contents/erysipelothrix-infection/abstract/26\" class=\"nounderline abstract_t\">Hardman SC, Carr SJ, Swann RA. Peritoneal dialysis-related peritonitis with bacteraemia due to Erysipelothrix rhusiopathiae. Nephrol Dial Transplant 2004; 19:1340.</a></li><li><a href=\"https://www.uptodate.com/contents/erysipelothrix-infection/abstract/27\" class=\"nounderline abstract_t\">Hocqueloux L, Poisson DM, Sunder S, et al. Septic arthritis caused by Erysipelothrix rhusiopathiae in a prosthetic knee joint. J Clin Microbiol 2010; 48:333.</a></li><li><a href=\"https://www.uptodate.com/contents/erysipelothrix-infection/abstract/28\" class=\"nounderline abstract_t\">Feasi M, Bacigalupo L, Cappato S, et al. Erysipelothrix rhusiopathiae intra-abdominal abscess. Int J Infect Dis 2010; 14:e81.</a></li><li><a href=\"https://www.uptodate.com/contents/erysipelothrix-infection/abstract/29\" class=\"nounderline abstract_t\">Romney M, Cheung S, Montessori V. Erysipelothrix rhusiopathiae endocarditis and presumed osteomyelitis. Can J Infect Dis 2001; 12:254.</a></li><li><a href=\"https://www.uptodate.com/contents/erysipelothrix-infection/abstract/30\" class=\"nounderline abstract_t\">Kim SR, Kwon MJ, Lee JH, Lee NY. Chronic meningitis caused by Erysipelothrix rhusiopathiae. J Med Microbiol 2007; 56:1405.</a></li><li><a href=\"https://www.uptodate.com/contents/erysipelothrix-infection/abstract/31\" class=\"nounderline abstract_t\">Traer EA, Williams MR, Keenan JN. Erysipelothrix rhusiopathiae infection of a total knee arthroplasty an occupational hazard. J Arthroplasty 2008; 23:609.</a></li><li><a href=\"https://www.uptodate.com/contents/erysipelothrix-infection/abstract/32\" class=\"nounderline abstract_t\">Elvy J, Hanspal I, Simcock P. A case of Erysipelothrix rhusiopathiae causing bilateral endogenous endophthalmitis. J Clin Pathol 2008; 61:1223.</a></li><li><a href=\"https://www.uptodate.com/contents/erysipelothrix-infection/abstract/33\" class=\"nounderline abstract_t\">Meric M, Ozcan SK. Erysipelothrix rhusiopathiae pneumonia in an immunocompetent patient. J Med Microbiol 2012; 61:450.</a></li><li><a href=\"https://www.uptodate.com/contents/erysipelothrix-infection/abstract/34\" class=\"nounderline abstract_t\">Andrychowski J, Jasielski P, Netczuk T, Czernicki Z. Empyema in spinal canal in thoracic region, abscesses in paravertebral space, spondylitis: in clinical course of zoonosis Erysipelothrix rhusiopathiae. Eur Spine J 2012; 21 Suppl 4:S557.</a></li><li><a href=\"https://www.uptodate.com/contents/erysipelothrix-infection/abstract/35\" class=\"nounderline abstract_t\">Dunbar SA, Clarridge JE 3rd. Potential errors in recognition of Erysipelothrix rhusiopathiae. J Clin Microbiol 2000; 38:1302.</a></li><li><a href=\"https://www.uptodate.com/contents/erysipelothrix-infection/abstract/36\" class=\"nounderline abstract_t\">Farfour E, Leto J, Barritault M, et al. Evaluation of the Andromas matrix-assisted laser desorption ionization-time of flight mass spectrometry system for identification of aerobically growing Gram-positive bacilli. J Clin Microbiol 2012; 50:2702.</a></li><li><a href=\"https://www.uptodate.com/contents/erysipelothrix-infection/abstract/37\" class=\"nounderline abstract_t\">Klauder JV. Erysipeloid as an occupational disease. JAMA 1938; 111:1345.</a></li><li><a href=\"https://www.uptodate.com/contents/erysipelothrix-infection/abstract/38\" class=\"nounderline abstract_t\">Venditti M, Gelfusa V, Tarasi A, et al. Antimicrobial susceptibilities of Erysipelothrix rhusiopathiae. Antimicrob Agents Chemother 1990; 34:2038.</a></li><li><a href=\"https://www.uptodate.com/contents/erysipelothrix-infection/abstract/39\" class=\"nounderline abstract_t\">Soriano F, Fern&aacute;ndez-Roblas R, Calvo R, Garc&iacute;a-Calvo G. In vitro susceptibilities of aerobic and facultative non-spore-forming gram-positive bacilli to HMR 3647 (RU 66647) and 14 other antimicrobials. Antimicrob Agents Chemother 1998; 42:1028.</a></li><li><a href=\"https://www.uptodate.com/contents/erysipelothrix-infection/abstract/40\" class=\"nounderline abstract_t\">Piper KE, Steckelberg JM, Patel R. In vitro activity of daptomycin against clinical isolates of Gram-positive bacteria. J Infect Chemother 2005; 11:207.</a></li><li><a href=\"https://www.uptodate.com/contents/erysipelothrix-infection/abstract/41\" class=\"nounderline abstract_t\">Jorgensen JH, Hindler JF. New consensus guidelines from the Clinical and Laboratory Standards Institute for antimicrobial susceptibility testing of infrequently isolated or fastidious bacteria. Clin Infect Dis 2007; 44:280.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 5537 Version 14.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H13\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">PATHOGENESIS</a></li><li><a href=\"#H3\" id=\"outline-link-H3\">CLINICAL MANIFESTATIONS</a><ul><li><a href=\"#H4\" id=\"outline-link-H4\">Localized cutaneous infection</a></li><li><a href=\"#H5\" id=\"outline-link-H5\">Diffuse cutaneous infection</a></li><li><a href=\"#H6\" id=\"outline-link-H6\">Systemic infection</a><ul><li><a href=\"#H7\" id=\"outline-link-H7\">- Endocarditis</a></li></ul></li><li><a href=\"#H8\" id=\"outline-link-H8\">Other manifestations</a></li></ul></li><li><a href=\"#H9\" id=\"outline-link-H9\">DIAGNOSIS</a></li><li><a href=\"#H1057147395\" id=\"outline-link-H1057147395\">DIFFERENTIAL DIAGNOSIS</a></li><li><a href=\"#H10\" id=\"outline-link-H10\">TREATMENT</a><ul><li><a href=\"#H11\" id=\"outline-link-H11\">Antibiotic susceptibility</a></li><li><a href=\"#H12\" id=\"outline-link-H12\">Clinical approach</a></li></ul></li><li><a href=\"#H13\" id=\"outline-link-H13\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"ID/5537|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=ID/73058\" class=\"graphic graphic_table\">- Treatment of Erysipelothrix</a></li></ul></li></ul></div></div>","javascript":null}